Eplerenon Krka Filmuhúðuð tafla 50 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

eplerenon krka filmuhúðuð tafla 50 mg

krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 50 mg

Ibandronic acid WH Filmuhúðuð tafla 50 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

ibandronic acid wh filmuhúðuð tafla 50 mg

williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 50 mg

Eplerenon Krka Filmuhúðuð tafla 25 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

eplerenon krka filmuhúðuð tafla 25 mg

krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 25 mg

Inspra Filmuhúðuð tafla 50 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

inspra filmuhúðuð tafla 50 mg

upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 50 mg

Inspra Filmuhúðuð tafla 25 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

inspra filmuhúðuð tafla 25 mg

upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 25 mg

Eplerenon Bluefish Filmuhúðuð tafla 50 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

eplerenon bluefish filmuhúðuð tafla 50 mg

bluefish pharmaceuticals ab - eplerenonum inn - filmuhúðuð tafla - 50 mg

Eplerenone Alvogen Filmuhúðuð tafla 25 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

eplerenone alvogen filmuhúðuð tafla 25 mg

alvogen ehf. - eplerenonum inn - filmuhúðuð tafla - 25 mg

Fulvestrant Teva Stungulyf, lausn í áfylltri sprautu 250 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

fulvestrant teva stungulyf, lausn í áfylltri sprautu 250 mg

teva b.v.* - fulvestrantum inn - stungulyf, lausn í áfylltri sprautu - 250 mg

Camzyos Den europeiske union - islandsk - EMA (European Medicines Agency)

camzyos

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - Önnur hjartablöndur - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Vidaza Den europeiske union - islandsk - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.